| Rotational radiotherapy for prostate cancer in clinical practice. | |
| | |
MedLine Citation:
|
PMID: 20970215 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Radiotherapy is the standard treatment in locally advanced prostate cancer. The latest technological improvement is modulated rotational radiotherapy, where one single rotation of the treatment machine is used to conform the dose delivery to the target and spare organs at risk, requiring less than 2 min of beam-on time per treatment fraction. MATERIALS AND METHODS: We report herein our experience from the first 46 patients treated for prostate cancer, clinical stage T1-3 with rotational therapy ("RapidArc®", Varian Medical systems) (RA). This patient group is compared to a group of 50 patients treated with a 5-field Intensity Modulated Radiation Therapy (IMRT) technique over the same period. The comparison parameters include target coverage, dose to OAR, treatment time and number of monitor units. Daily-IGRT using implanted gold markers is used before and after treatment to investigate intra-fractional prostate displacement. RESULTS: RA results in improved sparing of the rectum and achieves desired dose distributions with fewer monitor units and a shorter treatment time (<1.5 min versus up to 8.9 min with IMRT). This shorter treatment time also translates in a decreased risk of patient motion during treatment: daily-IGRT demonstrates reduced prostate motion (<3mm 3D vector) from 16.7% to 4.7% in RA patients. Only slight side-effects were seen in the two groups of patients. CONCLUSIONS: RA results in improved sparing of the rectum, however, at the expense of an increase in dose to the femoral heads in prostate patients. The treatment time is significantly reduced from 4.9 min on average with 5-field IMRT to 1.1 min with RA, which allows for a reduction of infractional prostate motion. |
| | |
Authors:
|
Marianne C Aznar; Peter Meidahl Petersen; Ashildur Logadottir; Henriette Lindberg; Stine S Korreman; Flemming Kjær-Kristoffersen; Svend Aage Engelholm |
Related Documents
:
|
18480625 - Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with si... 16372505 - Role of risk factors for erectile dysfunction in patients undergoing transurethral rese... 18353375 - The impact of prostate size on urinary quality of life indexes following laparoscopic r... 16406985 - Preoperative parameters, including percent positive biopsy, in predicting seminal vesic... 15839925 - The results of plaque incision and venous grafting (lue procedure) to correct the penil... 18480625 - Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with si... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-20 |
Journal Detail:
|
Title: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Volume: 97 ISSN: 1879-0887 ISO Abbreviation: Radiother Oncol Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8407192 Medline TA: Radiother Oncol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 480-4 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Department of Radiation Oncology, Rigshospitalet, Copenhagen, Denmark. marianne.aznar@rh.regionh.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Why avoid the hippocampus? A comprehensive review.
Next Document: Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carc...